> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Qinlock Regulatory Review Period Determined
- URL: https://www.fdaweb.com/qinlock-regulatory-review-period-determined/
- Published: 2021-11-15T12:00:00.000Z
- Updated: 2026-09-14T17:22:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150574

*Federal Register* notice: FDA determines for patent extension purposes the regulatory review period for Deciphera Pharmaceuticals’ Qinlock (ripretinib), indicated for treating adult patients with advanced gastrointestinal stromal tumors.